Calyxo vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Calyxo is a urology medical device company developing CVAC, a vacuum-assisted catheter for kidney stone fragment retrieval; raised $80M Series C in 2023;
About
Calyxo is a medical device company founded in 2017 and headquartered in Pleasanton, California, focused on improving outcomes in kidney stone treatment. The company's lead product is the CVAC System (Calyxo Vacuum-Assisted Catheter), an FDA-cleared ureteroscopy tool that uses suction to vacuum out kidney stone fragments during a single minimally invasive procedure. Traditional stone removal with a basket retrieval device requires multiple passes and often leaves residual fragments — a problem Calyxo's system addresses by continuously aspirating debris as the laser breaks up stones, achieving substantially higher stone-free rates in a single operating room session.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.